Navigation Links
SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services

Bound Brook, NJ (PRWEB) July 24, 2014

As part of the long-term strategic approach, DZS expects to manage numerous projects in the MENA region during 2014 with potential global expansion.

"We are delighted to have a preferred provider agreement with DZS to manage our clinical trials globally and in particular in the MENA region,” said Global VP of R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh Rehani. "DZS has developed excellent operational practices with a focus on utilizing eClinical software and flexible team structures that allow companies to reduce development costs yet maintain high quality services and meet timelines. This helps pharma companies to meet the many challenges of drug development."

“We are pleased to be able to partner with SBI at a strategic level. Our Sponsors are increasingly looking for innovative approaches to bring products to market effectively and efficiently,” said Greg Ambra, VP of Clinical Operations. “Our flexible project team models, collaborative approach, and proprietary eClinical Software, ClinPlus®, increases the level of collaboration and allows us to respond quickly to our Sponsor’s needs, while maintaining our focus on high quality deliverables.”

About DZS Clinical Services:
DZS Clinical Services is a full-service Contract Research Organization providing clinical trial services and eClinical software for the biotech and pharmaceutical industry. DZS Clinical Services is a division of DZS Software Solutions, Inc., a privately held company founded in 1984. Over 60 clients globally use DZS services and software for trial monitoring and management, data capture, data cleaning, analysis, and reporting. When ClinPlus® software is coupled with DZS services and training, clients have dramatically improved productivity and maximized the value of R&D investments by obtaining fast, high-quality results leading to better decisions.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
2. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
3. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
4. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
5. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
6. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
7. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
8. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
9. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
10. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
11. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
Breaking Biology Technology:
(Date:3/30/2017)... -- On April 6-7, 2017, will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
Breaking Biology News(10 mins):